PURPOSE: Cardiac sarcoidosis (CS) patients are at increased risk for sudden death. Isolated CS is rare and can be difficult to diagnose. METHODS: In this multicenter retrospective review, patients with CS and an implantable cardiac defibrillator (ICD) were identified. RESULTS: Of 235 patients with CS and ICD, 13 (5.5 %) had isolated CS, including 7 (3.0 %) with definite isolated CS (biopsy or necropsy-proven) and 6 (2.6 %) with suspected isolated CS based on a constellation of clinical, ECG, and imaging findings. Among 13 patients with isolated CS, 10 (76.9 %) were male, mean age was 53.8 ± 7.6 years, and mean left ventricular ejection fraction was 38.3 ± 16.5. Diagnosis was made by cardiac magnetic resonance (CMR) (n = 2), biopsy (n = 3), CMR and biopsy (n = 2), CMR and positron emission tomography (PET) (n = 2), PET (n = 1), late enhanced cardiac CT (n = 1), pathology at heart transplant (n = 1), and autopsy (n = 1). Eight of 13 (61.5 %) patients with isolated CS had a secondary prevention indication (VT in 6 and VF in 2) vs. 80 of 222 (36.0 %) with sarcoidosis in other organs (p = 0.04). Over a mean of 4.2 years, 9 of 13 (69.2 %) patients with isolated CS received appropriate ICD therapy, including anti-tachycardia pacing (ATP) and/or shock, compared with 75 of 222 (33.8 %) patients with cardiac and extracardiac sarcoidosis (p = 0.0150). Six of 7 (85.7 %) patients with definite isolated CS received appropriate ICD intervention, compared with 78 of 228 patients (34.2 %) without definite isolated CS (p = 0.0192.) CONCLUSIONS: In this retrospective study, patients with isolated CS had very high rates of appropriate ICD therapy. Prospective, long-term follow-up of consecutive patients with isolated CS is needed to determine the true natural history and rates of ventricular arrhythmias in this rare and difficult-to-diagnose disease.
PURPOSE:Cardiac sarcoidosis (CS) patients are at increased risk for sudden death. Isolated CS is rare and can be difficult to diagnose. METHODS: In this multicenter retrospective review, patients with CS and an implantable cardiac defibrillator (ICD) were identified. RESULTS: Of 235 patients with CS and ICD, 13 (5.5 %) had isolated CS, including 7 (3.0 %) with definite isolated CS (biopsy or necropsy-proven) and 6 (2.6 %) with suspected isolated CS based on a constellation of clinical, ECG, and imaging findings. Among 13 patients with isolated CS, 10 (76.9 %) were male, mean age was 53.8 ± 7.6 years, and mean left ventricular ejection fraction was 38.3 ± 16.5. Diagnosis was made by cardiac magnetic resonance (CMR) (n = 2), biopsy (n = 3), CMR and biopsy (n = 2), CMR and positron emission tomography (PET) (n = 2), PET (n = 1), late enhanced cardiac CT (n = 1), pathology at heart transplant (n = 1), and autopsy (n = 1). Eight of 13 (61.5 %) patients with isolated CS had a secondary prevention indication (VT in 6 and VF in 2) vs. 80 of 222 (36.0 %) with sarcoidosis in other organs (p = 0.04). Over a mean of 4.2 years, 9 of 13 (69.2 %) patients with isolated CS received appropriate ICD therapy, including anti-tachycardia pacing (ATP) and/or shock, compared with 75 of 222 (33.8 %) patients with cardiac and extracardiac sarcoidosis (p = 0.0150). Six of 7 (85.7 %) patients with definite isolated CS received appropriate ICD intervention, compared with 78 of 228 patients (34.2 %) without definite isolated CS (p = 0.0192.) CONCLUSIONS: In this retrospective study, patients with isolated CS had very high rates of appropriate ICD therapy. Prospective, long-term follow-up of consecutive patients with isolated CS is needed to determine the true natural history and rates of ventricular arrhythmias in this rare and difficult-to-diagnose disease.
Authors: Hossein Ardehali; David L Howard; Arvin Hariri; Atif Qasim; Joshua M Hare; Kenneth L Baughman; Edward K Kasper Journal: Am Heart J Date: 2005-09 Impact factor: 4.749
Authors: Luciano C Amado; Bernhard L Gerber; Sandeep N Gupta; Dan W Rettmann; Gilberto Szarf; Robert Schock; Khurram Nasir; Dara L Kraitchman; João A C Lima Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Pablo B Nery; Arieh Keren; Jeff Healey; Eugene Leug; Rob S Beanlands; David H Birnie Journal: Can J Cardiol Date: 2013-08 Impact factor: 5.223
Authors: Jordana Kron; William Sauer; Joseph Schuller; Frank Bogun; Thomas Crawford; Sinan Sarsam; Lynda Rosenfeld; Teferi Y Mitiku; Joshua M Cooper; Davendra Mehta; Arnold J Greenspon; Matthew Ortman; David B Delurgio; Ravinder Valadri; Calambur Narasimhan; Nalla Swapna; Jagmeet P Singh; Stephan Danik; Steven M Markowitz; Adrian K Almquist; Andrew D Krahn; Luke G Wolfe; Shawn Feinstein; Kenneth A Ellenbogen Journal: Europace Date: 2012-09-21 Impact factor: 5.214
Authors: Daniel Juneau; Fernanda Erthal; Benjamin J W Chow; Calum Redpath; Terrence D Ruddy; Juhani Knuuti; Rob S Beanlands Journal: J Nucl Cardiol Date: 2016-07-28 Impact factor: 5.952
Authors: G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno Journal: JACC Cardiovasc Imaging Date: 2016-07-20
Authors: David R Okada; Paco E Bravo; Tomas Vita; Vikram Agarwal; Michael T Osborne; Viviany R Taqueti; Hicham Skali; Panithaya Chareonthaitawee; Sharmila Dorbala; Garrick Stewart; Marcelo Di Carli; Ron Blankstein Journal: J Nucl Cardiol Date: 2016-09-09 Impact factor: 5.952
Authors: David G Rosenthal; Purvi Parwani; Tyler O Murray; Bradley J Petek; Bryan S Benn; Teresa De Marco; Edward P Gerstenfeld; Munir Janmohamed; Liviu Klein; Byron K Lee; Joshua D Moss; Melvin M Scheinman; Henry H Hsia; Van Selby; Laura L Koth; Miguel H Pampaloni; Julie Zikherman; Vasanth Vedantham Journal: J Am Heart Assoc Date: 2019-09-06 Impact factor: 5.501
Authors: C Anwar A Chahal; Peter A Brady; Leslie T Cooper; Grace Lin; Virend K Somers; Cynthia S Crowson; Eric L Matteson; Patompong Ungprasert Journal: J Am Heart Assoc Date: 2022-08-05 Impact factor: 6.106